-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Rochester, MN
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
-
A Study of Outcomes with Rituximab Induction versus Maintenance Treatments for IgG4-Related Diseases
Rochester, MN
The purpose of this study is to compare IgG4-related disease remission and relapse rates between patients who had induction rituximab treatment with or without follow-up maintenance rituximab therapy, at Mayo Clinic, Rochester between 1 January 2000 and 22 December 2015.
-
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Rochester, MN
This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD. If the addition of elotuzumab to prednisone is determined to be safe, Part 2: a randomized, placebo-controlled, double-blinded trial will be initiated. Part 2 will compare the effects of the addition of elotuzumab versus placebo to prednisone in participants with IgG4-RD. Approximately 75 participants with active IgG4-RD will be enrolled in the overall program, 12 in Part 1 and 63 in Part 2.